Nivolumab is commonly used for the treatment of renal cell carcinoma (RCC) due to the efficacy seen in past trials, including CheckMate 025 and CheckMate 214. Standard-of-care treatment for patients with intermediate- to high-risk RCC consists of partial or radical nephrectomy and surveillance, but a recent study by Mohamad E. Allaf, MD, and colleagues compared the use of nivolumab before nephrectomy followed by adjuvant nivolumab with surgery only in patients with high-risk RCC to determine which ...
Localized Renal Cell Carcinoma
Advertisement
Latest News
Dr. Albiges breaks down a biomarker analysis of circulating kidney injury molecule-1 in the IMmotion010 trial.
Researchers analyzed the connection between the outcomes and specific predictors of interest.
Previous studies investigating adjuvant therapy in patients with RCC have not included those with PSM.
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
Dr. Afari and colleagues sought to better understand factors leading to renal function improvement after partial nephrectomy.
For patients with primary RCC who are ineligible for surgical resection, SABR serves as a viable alternative.
Advertisement
Knowledge Hub Spotlight
Curated clinical content based on conditions, therapies, and technologies
Conference Coverage
Vishnu Murthy discusses the real-world efficacy and toxicity of 177Lu-PSMA-617 for mCRPC.
Rana McKay, MD, provides commentary on the safety of 89Zr-girentuximab PET/CT for treating clear cell renal cell carcinoma.
Dr. Calais provides his list of the clinical trials of interest on imaging, RLT, and prostate cancer from the SNMMI meeting.
Dr. Calais shares his thoughts on the sessions or abstracts that are of the most importance for practicing GU oncologists.
![PSMAfore Results: [177Lu]Lu-PSMA-617 in Taxane-Naive Patients With mCRPC](https://mumcdnstorage.blob.core.windows.net/guonc/2024/06/122-GUOnc_YouTube_Sartor_1280x720.jpg)
Dr. Sartor discusses the PSMAfore study, which examined [177Lu]Lu-PSMA-617 radioligand therapy in taxane-naive mCRPC.
Dr. Johnson provides an overview of the SECuRE study, a phase 1/2a theranostic trial for treatment of PSMA-expressing mCRPC.
Advertisement
Advertisement
Latest News
The genetic basis of HER2 overexpression other than ERBB2 amplification in UC is not well understood.
Researchers focused on the economic impact of disparities related to insurance coverage.
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
